Rapid Safety Assessment of SARS-CoV-2 Vaccines in EU Member States using Electronic Health Care Data Sources (COVID Vaccine Monitor-CVM study): Final Study Report for WP3 (electronic health record data)

Durán, CE, Messina, D, Gini, R, Riefolo, F, Aragón, M, Belitser, S, Bissacco, CA, Bots, SH, de Burgos, A, Carreras-Martínez, JJ, Correcher-Martínez, E, Douglas, IJORCID logo, Garcia-Poza, P, Girardi, A, Herings, R, Hoxhaj, V, Huerta, C, Hyeraci, G, Ientile, V, Ingrasciotta, Y, Limoncella, G, Lupattelli, A, Maglanoc, L, Martin, I, Martin, M, Mira-Iglesias, A, Mohammadi, S, Molero, E, Nordeng, H, Oberski, D, Overbeek, J, Pallejà, M, Riera-Arnau, J, Santacà, K, Siiskonen, S, Souverein, P, Schultze, AORCID logo, Swart, K, Trifirò, G, Urchueguía, A, Villalobos, F, Weibel, D, Zhao, J, Klungel, O and Sturkenboom, M (2023). Rapid Safety Assessment of SARS-CoV-2 Vaccines in EU Member States using Electronic Health Care Data Sources (COVID Vaccine Monitor-CVM study): Final Study Report for WP3 (electronic health record data). [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.10093613
Copy

In January 2021, the European Medicines Agency (EMA) launched a tender for safety monitoring of COVID-19 vaccines in the EU. The EU PE & PV and the VAC4EU network received and implemented the tender, which had two objectives, the first was to implement a prospective cohort for safety monitoring in more than 10 countries and the second was signal strengthening. This report is focusing on the second objective. Based on the technical specifications, signal strengthening meant the collection of additional information to further characterise the incidence of the safety concerns in comparison to its expected incidence in non- vaccinated populations or suitable comparator populations. Request of signal strengthening capacity was translated into two objectives: i) to create and assess readiness of electronic healthcare record data sources for rapid evaluation of safety signals by providing an overview of the methods to identify COVID-19 vaccine exposure in data sources, monitoring the number of individuals exposed to any COVID-19 vaccine, and the generation of updated background rates for Adverse Events of Special Interest, and ii) to conduct rapid safety assessment studies using electronic healthcare records and support EMA safety assessments.

Keywords

Safety, COVID-19, Vaccines, Adverse Events of Special Interest, Electronic health care data sources

No files available. Please consult associated links.


Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core (with Type as Type) MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON METS MODS RDF+N3 RDF+N-Triples RDF+XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads